The UK and US have established a important trade agreement that will keep zero tariffs on British pharmaceutical exports entering the American market.
The Terms of the Deal
Under the terms of the agreement, the UK has committed to increase funding on pharmaceuticals through the NHS. This pledge secures that duties on these key goods will remain at nothing for a timeframe of the next three years.
This agreement comes after previous statements to significantly raise duties on branded drug imports, with increases discussed reaching double the cost.
"This deal between the United Kingdom strengthens the international landscape for cutting-edge drugs and introduces long-overdue balance to transatlantic pharmaceutical trade," an announcement said.
Trade Impact
Pharmaceuticals constitute one of the UK's most significant goods shipped to the US, which is easily the primary destination for leading UK drugmakers.
Export figures show that in the year prior to the third quarter, the UK exported drugs totaling over eleven billion pounds to the US. This figure made up nearly one-fifth of total UK exports in that span.
"This deal secures jobs, stimulates investment and sets the stage for the UK to establish itself as a worldwide center for life sciences," a minister remarked.
Key NHS Changes
The deal entails several specific changes from the UK:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it judges new treatments to be too expensive by 25%.
- Higher Drug Budget: There is a aim to increase total health service expenditure on medicines from 0.3% of the national economy to 0.6% over the next decade.
- Payback Limit: The amount pharmaceutical firms must refund to the NHS to control costs will be capped at fifteen percent. In the past, repayments exceeded twenty percent.
Broader Context
The pact comes amid a long-running row between the drug companies and the ministers over spending levels and NHS adoption.
These tensions were intensified by assertions that American customers were paying a premium for the equivalent treatments than consumers in the other developed nations.
Over the last 18 months, several major pharmaceutical investments in the UK have been delayed or scrapped, while major funding commitments have been pledged toward projects in the United States.
A senior figure acknowledged that the NHS needed to spend more on medicines, noting that its spending on drugs had decreased as a percentage of its total funding over the past decade.
